By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Repros Therapeutics Inc. 

2408 Timberloch Place
Suite B-7
The Woodlands  Texas  77380  U.S.A.
Phone: 281-719-3400 Fax: 281-719-3446


Company News
10 Major Pharma and FDA Catalysts Coming in December 12/6/2016 6:22:00 AM
Repros Therapeutics (RPRX) Reports Topline Positive Clinical Data After Two 18 Week Courses Of Proellex Delivered Orally And Vaginally For The Treatment Of Uterine Fibroids 11/15/2016 10:47:15 AM
Repros Therapeutics (RPRX) Reports Third Quarter 2016 Financial Results 11/9/2016 8:38:15 AM
Repros Therapeutics (RPRX) Announces Acceptance Of Dossier For Enclomiphene For Secondary Hypogonadism By European Authorities 10/6/2016 7:30:16 AM
Repros Therapeutics (RPRX) Release: FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism 9/26/2016 7:47:38 AM
Repros Therapeutics (RPRX) Announces Submission Of MAA To The EMA For Enclomiphene In The Treatment Of Secondary Hypogonadism 9/13/2016 10:05:38 AM
Repros Therapeutics (RPRX) Provides Phase II Results Showing Positive Outcomes For Oral Proellex In Women With Moderate To Severe Endometriosis 9/8/2016 8:32:14 AM
Repros Therapeutics (RPRX) Reports Second Quarter 2016 Financial Results 8/9/2016 8:44:33 AM
Repros Therapeutics (RPRX) to Ditch Efforts to Seek Approval of Testosterone Drug in the U.S. if Key Study Fails 4/15/2016 6:44:41 AM
Repros Therapeutics (RPRX) Skyrockets Premarket Following Positive Clinical Data for Vaginal Proellex 4/13/2016 6:14:33 AM